¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ jM:Y ' l]  
p^iRPI  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© ( 9]_ HW[  
yObuWDA9  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© xTGxvGv8  
BI j=!!  
1.Co-stimulators (or co-stimulating molecules) J6<rX[ yZe  
YSaJeU>@  
2.NK-kB X=C1/4wU  
u=YX9Mo!  
3.Immunoglobulin superfamily |X` /  
` \A(9u*  
4.antigen-presenting cell (APC) 7u[j/l,  
we#wH-  
5.death domain V)P&Zw  
<9sO  
6.CCR and CXCR [TCP-bU  
X w.p  
7.Lectin (or mitogen) ?:Y#Tbi3  
w{dIFvQ"$  
8.Clusters of differentiation, CD) x3rlJs`$;  
%Qmk2  
9.B7 family -TZ p FT"  
=H<0o?8?c  
10.Cytotoxic T lymphocyte, CTL) MZ+e}|!4,  
Bb{!Yh].:A  
11.IL-15 and IL-15 receptor (IL-15R) {_U Kttp  
wDwH.~3!  
12.MHC restriction kw`WH)+F  
al+ #y)+  
13.Affinity-chromatography ""s vDfy$  
1oKfy>ie  
14.Cyctosprin A, CsA "g+z !4b#  
`c+/q2M  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) aiCn"j  
~m*,mz  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© IHC1G1KW=A  
oR p:B &  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 hO[3Z ^X  
LEECW_:  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ (5^ZlOk3  
@ d"wAZzD?  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ \M]-bw`  
UofTl l)  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 7~M<cD  
V[a[i>,Z  
ÃâÒßѧרҵ£º U/;]zdP.K  
#=}$OFg  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£  uIMe  
`B8tmW#  
Ïû»¯ÄÚ¿Æ£º $\AEWFB  
K t#, ]]  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ Eaad,VBtU  
^%y`u1ab  
ѪҺ²¡Ñ§×¨Òµ£º r+<{S\ Q  
F=)eLE{W  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»